VentureRadar helps organizations innovate and generate new growth by connecting them to emerging technologies and expertise that can solve their challenges. They discover innovative companies globally using their Company Discovery Engine, which aggregates company information at a scale, speed, and efficiency that hasn’t previously been possible. By structuring and analyzing this information, they accurately match clients' needs with start-ups, SMEs, and other innovators with the required skills. They work directly with corporations and service providers to provide intelligent company discovery capabilities.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CDAK

COM:CODIAKBIO

VentureRadar

Last Close

0.06

19/08 20:00

Market Cap

2.83M

Beta: -

Volume Today

14.21M

Avg: -

market

industry

website

crunchbase

ipo date

peer of

Metrics